Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome-Coronavirus Spike Protein

被引：8

作者：

Raadsen, Matthijs P. ^{[1
]}

Dahlke, Christine ^{[2
,3
,4
]}

Fathi, Anahita ^{[2
,3
,4
,5
]}

Lamers, Mart M. ^{[1
]}

van den Doel, Petra ^{[1
]}

Zaeck, Luca M. ^{[1
]}

van Royen, Martin E. ^{[6
]}

de Bruin, Erwin ^{[1
,7
]}

Sikkema, Reina ^{[1
]}

Koopmans, Marion ^{[1
]}

van Gorp, Eric C. M. ^{[1
]}

Sutter, Gerd ^{[8
,9
]}

de Vries, Rory D. ^{[1
]}

Addo, Marylyn M. ^{[2
,3
,4
,5
,11
]}

Haagmans, Bart L. ^{[1
,10
]}

机构：

[1] Erasmus MC, Dept Virosci, Rotterdam, Netherlands

[2] Univ Med Ctr Hamburg Eppendorf, Inst Infect Res & Vaccine Dev IIRVD, Hamburg, Germany

[3] Bernhard Nocht Inst Trop Med, Dept Clin Immunol Infect Dis, Hamburg, Germany

[4] German Ctr Infect Res, Partner site Hamburg Lubeck Borstel Riems, Hamburg, Germany

[5] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Div Infect Dis, Hamburg, Germany

[6] Erasmus MC, Dept Pathol, Rotterdam, Netherlands

[7] Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Div Pathol, Utrecht, Netherlands

[8] LMU Univ Munich, Inst Infect Dis & Zoonoses, Div Virol, Munich, Germany

[9] German Ctr Infect Res, Partner Site Munich, Munich, Germany

[10] Erasmus MC, Dept Virosci, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands

[11] Univ Med Ctr Hamburg Eppendorf, Inst Infect Res & Vaccine Dev IIRVD, Martinistr 52, D-20246 Hamburg, Germany

来源：

JOURNAL OF INFECTIOUS DISEASES | 2023年 / 228卷 / 05期

关键词：

Middle East respiratory syndrome-related coronavirus; MPXV; MVA; modified vaccinia virus Ankara; monkeypox virus; IMMUNOGENICITY; EFFICACY; SAFETY;

D O I：

10.1093/infdis/jiad052

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A modified vaccinia virus Ankara-based candidate vaccine against Middle East respiratory syndrome-associated coronavirus elicits monkeypox virus neutralizing antibodies after 3 doses in healthy clinical trial participants. Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.

引用

页码：586 / 590

页数：5

共 15 条

[1] Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19
Aguilar-Bretones, Muriel
Westerhuis, Brenda M.
Raadsen, Matthijs P.
de Bruin, Erwin
Chandler, Felicity D.
Okba, Nisreen M. A.
Haagmans, Bart L.
Langerak, Thomas
Endeman, Henrik
van den Akker, Johannes P. C.
Gommers, Diederik A. M. P. J.
van Gorp, Eric C. M.
GeurtsvanKessel, Corine H.
de Vries, Rory D.
Fouchier, Ron A. M.
Rockx, Barry H. G.
Koopmans, Marion P. G.
van Nierop, Gijsbert P.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (21)
[2] [Anonymous], 2017, WHO TARG PROD PROF M
[3] [Anonymous], 2019, FDA Approves First Live, Non-Replicating Vaccine to Prevent Smallpox and Monkeypox
[4] Arbel R., 2022, ResSq, DOI [10.21203/rs.3.rs-1976861/v1, DOI 10.21203/RS.3.RS-1976861/V1]
[5] Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Fathi, Anahita
Dahlke, Christine
Krahling, Verena
Kupke, Alexandra
Okba, Nisreen M. A.
Raadsen, Matthijs P.
Heidepriem, Jasmin
Muller, Marcel A.
Paris, Grigori
Lassen, Susan
Kluver, Michael
Volz, Asisa
Koch, Till
Ly, My L.
Friedrich, Monika
Fux, Robert
Tscherne, Alina
Kalodimou, Georgia
Schmiedel, Stefan
Corman, Victor M.
Hesterkamp, Thomas
Drosten, Christian
Loeffler, Felix F.
Haagmans, Bart L.
Sutter, Gerd
Becker, Stephan
Addo, Marylyn M.
[J]. NATURE COMMUNICATIONS, 2022, 13 (01)
[6] Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge
Frey, Sharon E.
Newman, Frances K.
Kennedy, Jeffrey S.
Sobek, Vera
Ennis, Francis A.
Hill, Heather
Yan, Lihan K.
Chaplin, Paul
Vollmar, Jens
Chaitman, Bernard R.
Belshe, Robert B.
[J]. VACCINE, 2007, 25 (51) : 8562 - 8573
[7] Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects
Greenberg, Richard N.
Overton, Edgar Turner
Haas, David W.
Frank, Ian
Goldman, Mitchell
von Krempelhuber, Alfred
Virgin, Garth
Baedeker, Nicole
Vollmar, Jens
Chaplin, Paul
[J]. JOURNAL OF INFECTIOUS DISEASES, 2013, 207 (05) : 749 - 758
[8] Analysis of Variola and Vaccinia Virus Neutralization Assays for Smallpox Vaccines
Hughes, Christine M.
Newman, Frances K.
Davidson, Whitni B.
Olson, Victoria A.
Smith, Scott K.
Holman, Robert C.
Yan, Lihan
Frey, Sharon E.
Belshe, Robert B.
Karem, Kevin L.
Damon, Inger K.
[J]. CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (07) : 1116 - 1118
[9] Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open -label, phase 1 trial
Koch, Till
Dahlke, Christine
Fathi, Anahita
Kupke, Alexandra
Kraehling, Verena
Okba, Nisreen M. A.
Halwe, Sandro
Rohde, Cornelius
Eickmann, Markus
Volz, Asisa
Hesterkamp, Thomas
Jambrecina, Alen
Borregaard, Saskia
Ly, My L.
Zinser, Madeleine E.
Bartels, Etienne
Poetsch, Joseph S. H.
Neumann, Reza
Fux, Robert
Schmiedel, Stefan
Lohse, Ansgar W.
Haagmans, Bart L.
Sutter, Gerd
Becker, Stephan
Addo, Marylyn M.
[J]. LANCET INFECTIOUS DISEASES, 2020, 20 (07) : 827 - 838
[10] Kreijtz JHCM, 2014, LANCET INFECT DIS, V14, P1196, DOI [10.1016/s1473-3099(14)70963-6, 10.1016/S1473-3099(14)70963-6]

← 1 2 →